PJS-539 / CoviCept Therap - LARVOL DELTA

Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial. (PubMed, PLoS One) - "Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days."

Clinical • Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy of PJS-539 for Adult Patients With COVID-19. (clinicaltrials.gov) - P2 | N=153 | Completed | Sponsor: Hospital do Coracao | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Efficacy of PJS-539 for Adult Patients With COVID-19. (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: Hospital do Coracao | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Efficacy of PJS-539 for Adult Patients With COVID-19. (clinicaltrials.gov) - P2; N=150; Recruiting; Sponsor: Hospital do Coracao; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • PCR

Efficacy of PJS-539 for Adult Patients With SARS-Cov-2. (clinicaltrials.gov) - P2; N=150; Not yet recruiting; Sponsor: Hospital do Coracao

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases